Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05013632 · ClinicalTrials.gov registry record
COVID-19 International Drug Pregnancy Registry
A clinical trial of COVID-19, sponsored by Pregistry.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT05013632: Recruiting study of COVID-19, sponsored by Pregistry.
NCT05013632 is a study of COVID-19 that is actively recruiting participants, run by Pregistry. The registered enrollment target is 2,000 participants, below the 38,458-participant average among 298 other COVID-19 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05013632, a study of COVID-19, is actively recruiting participants, sponsored by Pregistry.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.
Primary Outcome
Number of pregnant women who received at least one dose of a monoclonal antibody or antiviral drug indicated for the treatment of mild, moderate, or severe COVID-19 and number of pregnant women in the reference cohorts who experience spontaneous abortion, intrauterine growth restriction, gestational diabetes, gestational hypertension, postpartum hemorrhage, Caesarean delivery.
Conditions Studied
Interventions
- DRUG Antiviral Agents
- DRUG Monoclonal antibody
Study Locations (1)
California
- Pregistry - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2027-09-30 |
What NCT05013632 shows while recruiting
NCT05013632 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, below the 38,458-participant average among 298 other COVID-19 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Antiviral Agents is the first listed.
NCT05013632 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05013632 about?
NCT05013632 is a clinical study titled "COVID-19 International Drug Pregnancy Registry". The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (L...
What is the current status of trial NCT05013632?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2021-12-01. Estimated completion is 2027-09-30.
What conditions does trial NCT05013632 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05013632?
The interventions under investigation include: Antiviral Agents (DRUG), Monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT05013632?
This trial is sponsored by Pregistry, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05013632 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05013632's enrollment target sits among peer trials
2,000 44th of 298 higher than 254 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI